Company news
Bioxcel Therapeutics, Inc. (NASDAQ:BTAI) news
Bioxcel Therapeutics, Inc. news releases on 6ix. Latest, Feb 8, 2023: BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company’s…
Press releases — page 3
BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company’s Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer
February 7, 2023
BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer
January 10, 2023
BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
December 21, 2022
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
December 18, 2022
BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia
November 29, 2022
BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
November 9, 2022
BioXcel Therapeutics to Host IGALMI™ Commercial Day on October 18, 2022
October 4, 2022
BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
August 8, 2022
BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal
July 31, 2022
BioXcel Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
July 25, 2022
BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors
July 4, 2022
BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference
May 19, 2022
BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights
May 8, 2022
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
May 2, 2022
BioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022
April 25, 2022
BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology
April 18, 2022
BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority
April 18, 2022
BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults
April 5, 2022
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
March 9, 2022
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
February 23, 2022
BioXcel Therapeutics Announces Journal of the American Medical Association Publication of Data from SERENITY II Pivotal Phase 3 Trial Evaluating BXCL501 in Bipolar Disorders
February 21, 2022
BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2022 ASCO Genitourinary Cancers Symposium
February 13, 2022
BioXcel Therapeutics Appoints Matt Wiley Chief Commercial Officer
January 18, 2022
BioXcel Therapeutics Initiates Pivotal Phase 3 Program of BXCL501 for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
December 14, 2021
BioXcel Therapeutics Announces Extension of FDA Review Period of its NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders
November 30, 2021
BioXcel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Operational Highlights
November 9, 2021
BioXcel Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021
October 26, 2021
BioXcel Therapeutics Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer
October 17, 2021
BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with KEYTRUDA® in Aggressive Forms of Prostate Cancer at ESMO
September 14, 2021
BioXcel Therapeutics to Host Virtual R&D Day on September 23, 2021
September 8, 2021
BioXcel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
August 9, 2021
BioXcel Therapeutics to Report Second Quarter 2021 Financial Results on August 10, 2021
July 27, 2021
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
June 22, 2021
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
June 21, 2021
BioXcel Therapeutics to Host Virtual Commercial Day on June 25, 2021
June 17, 2021
BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II
May 18, 2021
BioXcel Therapeutics Announces Presentations at the ISBD 2021 Global Annual Conference
May 10, 2021
BioXcel Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 9, 2021
BioXcel Therapeutics Launches “Boiling Point” Educational Campaign to Shed Light on the Importance of Prompt and Cooperative De-escalation in the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders
April 28, 2021
BioXcel Therapeutics Announces Presentations on SERENITY I & II at the 2021 American Psychiatric Association Annual Meeting
April 25, 2021
BioXcel Therapeutics Announces Results of Phase 1b/2 Study of BXCL501 for the Treatment of Opioid Withdrawal Symptoms
March 30, 2021
BioXcel Therapeutics Receives FDA Breakthrough Therapy Designation for BXCL501 for the Acute Treatment of Agitation Associated with Dementia
March 14, 2021
BioXcel Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders
March 10, 2021
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 10, 2021
BioXcel Therapeutics Provides Update on its BXCL501 Program for the Acute Treatment of Dementia Related Agitation
March 2, 2021
BioXcel Therapeutics Appoints June Bray to Board of Directors
February 28, 2021
BioXcel Therapeutics Announces Initiation of Phase 2 PLACIDITY Trial of BXCL501 for the Treatment of Delirium Related Agitation
February 24, 2021
BioXcel Therapeutics Appoints Javier Rodriguez as Chief Legal Officer and Corporate Secretary
February 22, 2021
BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the TRANQUILITY Phase 1b/2 Study for the Acute Treatment of Agitation in Dementia, including Alzheimer’s Disease
January 4, 2021
BioXcel Therapeutics Announces Grant by U.S. Department of Defense to Evaluate BXCL501 in Patients Suffering from PTSD
December 6, 2020